USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Bristol Myers Squibb New Drug Sales Overtake Legacy Drugs

The Motley Fool +1 · ·by G4L

BMY Bristol-Myers Squibb Co
$63.43 +1.78%
View chart & analysis →
  1. 1Bristol Myers Squibb is facing the expiration of patent protections for its existing drugs.
  2. 2Bristol Myers Squibb's growth portfolio recorded $7.66 billion in sales in the third quarter of 2026.
  3. 3Eliquis is currently recording $4.69 billion in sales.

So what's the key point?

Bristol Myers Squibb's new drugs have surpassed the sales of its older drugs. This means that as patents for existing drugs expire, the new drugs have generated $7.66 billion in sales.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

BioNTech and Moderna Compete to Expand Beyond COVID-19 Vaccines into Cancer Treatment Market The Motley Fool +1 · 5d agoBristol Myers Squibb Beats Third-Quarter Net Income and Revenue Estimates The Wall Street Journal +6 · Oct 29Bristol Myers Squibb Announces Patient Death in Multiple Sclerosis Clinical Trial Stocktwits +1 · Oct 24
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news